Suvretta Capital Management, LLC Mirati Therapeutics, Inc. Transaction History

Suvretta Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $17.3 Million - $39.2 Million	441,655 Added 86.54%	951,986 $63.9 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $8.15 Million - $16.2 Million	107,542 Added 26.7%	510,331 $42 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $27.9 Million - $40.2 Million	211,481 Added 110.54%	402,789 $59.1 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $5.61 Million - $7.53 Million	42,436 Added 28.51%	191,308 $33.8 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $21.4 Million - $26.8 Million	148,872 New	148,872 $24 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Suvretta Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Suvretta Capital Management, LLC with notifications on news.